(Q39042851)

8 September 2017

title

Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism (English)

1 reference

8 September 2017

0 references

0 references

1 reference

9

Sang-Uk Han

1 reference

8 September 2017

2

Hoon Hur

1 reference

8 September 2017

Yi Xuan

1

1 reference

8 September 2017

In-Hye Ham

3

1 reference

8 September 2017

Jisoo Yun

4

1 reference

8 September 2017

Ji-Yoon Lee

5

1 reference

8 September 2017

Wooyoung Shim

6

1 reference

8 September 2017

Young Bae Kim

7

1 reference

8 September 2017

Gwang Lee

8

1 reference

8 September 2017

Yong Kwan Cho

10

1 reference

8 September 2017

language of work or name

English

0 references

publication date

14 December 2013

1 reference

Experimental Cell Research

8 September 2017

published in

1 reference

8 September 2017

volume

321

1 reference

8 September 2017

issue

2

1 reference

8 September 2017

page(s)

219-230

1 reference

Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Chemotherapy for metastatic gastric cancer in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

5-Fluorouracil: mechanisms of action and clinical strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Hypoxia and drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Dichloroacetate induces apoptosis in endometrial cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Metabolic modulation of glioblastoma with dichloroacetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Hypoxia--a key regulatory factor in tumour growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Targeting HIF-1 for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Effect of antisense hypoxia-inducible factor 1alpha on progression, metastasis, and chemosensitivity of pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Hypoxia, clonal selection, and the role of HIF-1 in tumor progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

HIF-1 and tumor progression: pathophysiology and therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Recent agents targeting HIF-1α for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Detecting recurrence of gastric cancer: the value of FDG PET/CT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Predicting the response to chemotherapy in gastric adenocarcinoma: who benefits from neoadjuvant chemotherapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

SUVmax of FDG-PET correlates with the effects of neoadjuvant chemoradiotherapy for oral squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Treatment of lactic acidosis with dichloroacetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

A concomitant ATP-depleting strategy markedly enhances anticancer agent activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

Involvement of tyrosine kinase p56/Lck in apoptosis induction by anticancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2013.12.009

10.1016/J.YEXCR.2013.12.009

7 January 2021

Identifiers

DOI

1 reference

8 September 2017

1 reference